Vitrification: an effective new approach to oocyte banking and preserving fertility in cancer patients

Cancer patients require a complex multidisciplinary therapy. In this context the 3D additive biological manufacturing could represent a significant development with potential significant medical and social consequences. This article reviews the 3D bioprinting methods and clinical settings in which this new revolutionary method could be applied. Apart from the actual field of post-cancer therapy prosthetics and medical education, this method could be applied in the actual molecular cancer research and organ regeneration/fabrication. Considering all of these, it is possible that in the future, 3D biological printing could be used on a regular basis in clinical oncology.

Download Full-text

Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression

Medical Oncology ◽

10.1007/s12032-017-0965-7 ◽

2017 ◽

Vol 34 (6) ◽

Cited By ~ 12

Author(s):

Daniela Alterio ◽

Giulia Marvaso ◽

Fausto Maffini ◽

Sara Gandini ◽

Susanna Chiocca ◽

...

Keyword(s):

Head And Neck Cancer ◽

Prognostic Factor ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Postoperative Radiotherapy ◽

New Approach

Download Full-text

New Approach for Collecting Cancer Patients’ Views and Preferences Through Medical Staff

Patient Preference and Adherence ◽

10.2147/ppa.s292239 ◽

2021 ◽

Vol Volume 15 ◽

pp. 375-385

Author(s):

Tomoko Takayama ◽

Yoji Inoue ◽

Rie Yokota ◽

Masayo Hayakawa ◽

Chikako Yamaki ◽

...

Keyword(s):

Cancer Patients ◽

Medical Staff ◽

New Approach

Download Full-text

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

Breast Care ◽

10.1159/000486330 ◽

2018 ◽

Vol 13 (1) ◽

pp. 22-26

Author(s):

Florian Schütz ◽

Frederik Marmé ◽

Christoph Domschke ◽

Christof Sohn ◽

Alexandra von Au

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

New Technologies ◽

Breast Cancer Patients ◽

New Approach ◽

Tumor Associated Antigen ◽

Specific Tumor ◽

Car T ◽

Passive Vaccination ◽

Near Future

Immunotherapies are set to become part of the therapeutic repertoire for breast cancer in the near future. Active vaccination is a promising strategy, especially in tumors that have a specific tumor-associated antigen. Although cellular immunotherapies have not yet shown efficacy, new technologies are on the way to improve this approach. Given the recent Food and Drug Administration approval of chimeric antigen receptor (CAR) T cells for leukemia, it is only a question of time before solid tumors will follow. However, not all breast cancer patients will respond to cellular or other immunotherapy. Hence, we must define subpopulations of breast cancer patients who benefit from this new approach.

Download Full-text